{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:11:35Z","timestamp":1772136695462,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]},{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]},{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]},{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]},{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]},{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]},{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]},{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]},{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]},{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]},{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]},{"name":"German Federal Ministry of Education and Research","award":["16GW0219K"],"award-info":[{"award-number":["16GW0219K"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Drug Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antimicrobial resistance poses a fundamental global threat, necessitating new strategies for effective therapies. Cystobactamids, a class of antibacterial agents targeting bacterial gyrase and topoisomerase IV, represent a non-traditional chemical scaffold with broad-spectrum activity. For toxicological de-risking, we performed a comprehensive profiling on eukaryotic cells, focusing on cytotoxicity, genotoxicity, and mitochondrial toxicity, demonstrating cellular safety and superoxide scavenging properties. Studies in zebrafish embryos assessed developmental, cardiovascular, and hepatic toxicity, indicating a favorable in vivo safety profile. Metabolism studies revealed glucuronidation and amide bond hydrolysis as key pathways, whereby cystobactamid metabolic stability substantially improved by cobicistat co-treatment. Affinity-based protein profiling identified the cholesterol- and HCV-receptor scavenger receptor class B member 1 (SCARB1) as a primary eukaryotic off-target protein, with cystobactamids shown to inhibit SCARB1\u00b4s function, preventing hepatitis C virus pseudoparticle entry into cells. These findings suggest a high therapeutic potential for cystobactamids and highlight SCARB1 as a primary eukaryotic target.<\/jats:p>","DOI":"10.1038\/s44386-025-00020-7","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T05:14:45Z","timestamp":1754457285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cystobactamid off-target profiling reveals favorable safety, superoxide reduction, and SCARB1 inhibition in eukaryotes"],"prefix":"10.1038","volume":"2","author":[{"given":"Timo","family":"Risch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Hellwinkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas M.","family":"Kany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Solga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Seedorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Heimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Hoppst\u00e4dter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kohnh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jil-Sophie","family":"Hilgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Fries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Deschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Br\u00f6nstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kirschning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan A.","family":"Sieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pietschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra K.","family":"Kiemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"20_CR1","unstructured":"WHO. WHO Bacterial Priority Pathogens List, 2024 (WHO, 2024)."},{"key":"20_CR2","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMp1408040","volume":"371","author":"C Nathan","year":"2014","unstructured":"Nathan, C. & Cars, O. Antibiotic resistance\u2014problems, progress, and prospects. New Engll. J. Med. 371, 1761\u20131763 (2014).","journal-title":"New Engll. J. Med."},{"key":"20_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1469-0691.2008.02126.x","volume":"14","author":"GM Rossolini","year":"2008","unstructured":"Rossolini, G. M. & Mantengoli, E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin. Microbiol. Infect. 14, 2\u20138 (2008).","journal-title":"Clin. Microbiol. Infect."},{"key":"20_CR4","unstructured":"European Medicines Agency. The European Medicines Agency Road map to 2015: The Agency \u2019 s Contribution to Science, Medicines, Health. 44, (2015)."},{"key":"20_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41429-023-00629-8","volume":"76","author":"MS Butler","year":"2023","unstructured":"Butler, M. S., Henderson, I. R., Capon, R. J. & Blaskovich, M. A. T. Antibiotics in the clinical pipeline as of December 2022. J. Antibiot. 76, 431\u2013473 (2023). 2023 768.","journal-title":"J. Antibiot."},{"key":"20_CR6","doi-asserted-by":"publisher","first-page":"14605","DOI":"10.1002\/anie.201409964","volume":"53","author":"S Baumann","year":"2014","unstructured":"Baumann, S. et al. Cystobactamids: myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity. Angew. Chemie - Int. Ed. 53, 14605\u201314609 (2014).","journal-title":"Angew. Chemie - Int. Ed."},{"key":"20_CR7","doi-asserted-by":"publisher","first-page":"12760","DOI":"10.1002\/anie.201705913","volume":"56","author":"S H\u00fcttel","year":"2017","unstructured":"H\u00fcttel, S. et al. Discovery and total synthesis of natural cystobactamid derivatives with superior activity against gram-negative pathogens. Angew. Chemie Int. Ed. 56, 12760\u201312764 (2017).","journal-title":"Angew. Chemie Int. Ed."},{"key":"20_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41929-022-00904-1","volume":"6","author":"E Michalczyk","year":"2023","unstructured":"Michalczyk, E. et al. Molecular mechanism of topoisomerase poisoning by the peptide antibiotic albicidin. Nat. Catal. 6, 52\u201367 (2023).","journal-title":"Nat. Catal."},{"key":"20_CR9","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1021\/acs.jnatprod.6b00294","volume":"79","author":"YJ Kim","year":"2016","unstructured":"Kim, Y. J. et al. Isolation of Coralmycins A and B, potent anti-gram negative compounds from the Myxobacteria Corallococcus coralloides M23. J. Nat. Prod. 79, 2223\u20132228 (2016).","journal-title":"J. Nat. Prod."},{"key":"20_CR10","doi-asserted-by":"crossref","unstructured":"Hashimi, S. M. Albicidin, a potent DNA gyrase inhibitor with clinical potential. J. Antibiot. (Tokyo). 72, 785\u2013792 (2019).","DOI":"10.1038\/s41429-019-0228-2"},{"key":"20_CR11","doi-asserted-by":"publisher","first-page":"7219","DOI":"10.1002\/chem.202000117","volume":"26","author":"WAM Elgaher","year":"2020","unstructured":"Elgaher, W. A. M. et al. Cystobactamid 507: concise synthesis, mode of action, and optimization toward more potent antibiotics. Chem. - A Eur. J. 26, 7219\u20137225 (2020).","journal-title":"Chem. - A Eur. J."},{"key":"20_CR12","doi-asserted-by":"publisher","first-page":"12755","DOI":"10.1002\/anie.201705387","volume":"56","author":"B Cheng","year":"2017","unstructured":"Cheng, B., M\u00fcller, R. & Trauner, D. Total syntheses of cystobactamids and structural confirmation of Cystobactamid 919-2. Angew. Chem.\u2014Int. Ed. 56, 12755\u201312759 (2017).","journal-title":"Angew. Chem.\u2014Int. Ed."},{"key":"20_CR13","doi-asserted-by":"crossref","unstructured":"Risch, T. et al. YgiV promoter mutations cause resistance to cystobactamids and reduced virulence factor expression in Escherichia coli. NPJ Antimicrob. Resist. 2, 33 (2024).","DOI":"10.1038\/s44259-024-00050-7"},{"key":"20_CR14","doi-asserted-by":"publisher","first-page":"8369","DOI":"10.1021\/acs.orglett.9b03143","volume":"21","author":"M Moeller","year":"2019","unstructured":"Moeller, M. et al. Scalable syntheses of methoxyaspartate and preparation of the antibiotic Cystobactamid 861-2 and highly potent derivatives. Org. Lett. 21, 8369\u20138372 (2019).","journal-title":"Org. Lett."},{"key":"20_CR15","doi-asserted-by":"crossref","unstructured":"Testolin, G. et al. Synthetic studies of cystobactamids as antibiotics and bacterial imaging carriers lead to compounds with high in vivo efficacy. Chem. Sci. 11, 1316\u20131334 (2020).","DOI":"10.1039\/C9SC04769G"},{"key":"20_CR16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nrd.2016.184","volume":"15","author":"RK Harrison","year":"2016","unstructured":"Harrison, R. K. Phase II and phase III failures: 2013-2015. Nat. Rev. Drug Discov. 15, 817\u2013818 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"20_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrd4090","volume":"12","author":"J Arrowsmith","year":"2013","unstructured":"Arrowsmith, J. & Miller, P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat. Rev. Drug Discov. 12, 569 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"20_CR18","first-page":"362","volume":"14","author":"MS Lipsky","year":"2001","unstructured":"Lipsky, M. S. & Sharp, L. K. From idea to market: the drug approval process. J. Am. Board Fam. Pract. 14, 362\u2013367 (2001).","journal-title":"J. Am. Board Fam. Pract."},{"key":"20_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd3801","volume":"11","author":"PY Muller","year":"2012","unstructured":"Muller, P. Y. & Milton, M. N. The determination and interpretation of the therapeutic index in drug development. Nat. Rev. Drug Discov. 11, 751\u2013761 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"20_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/med.21445","volume":"38","author":"S Kalyaanamoorthy","year":"2018","unstructured":"Kalyaanamoorthy, S. & Barakat, K. H. Development of safe drugs: the hERG challenge. Med. Res. Rev. 38, 525\u2013555 (2018).","journal-title":"Med. Res. Rev."},{"key":"20_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","volume":"58","author":"WS Redfern","year":"2003","unstructured":"Redfern, W. S. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32\u201345 (2003).","journal-title":"Cardiovasc. Res."},{"key":"20_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.toxlet.2005.07.001","volume":"160","author":"G Fotakis","year":"2006","unstructured":"Fotakis, G. & Timbrell, J. A. In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol. Lett. 160, 171\u2013177 (2006).","journal-title":"Toxicol. Lett."},{"key":"20_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185\u2013229 (2004).","journal-title":"Pharmacol. Rev."},{"key":"20_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/1074-5521(95)90120-5","volume":"2","author":"M Tomasz","year":"1995","unstructured":"Tomasz, M. Mitomycin C: small, fast and deadly (but very selective). Chem. Biol. 2, 575\u2013579 (1995).","journal-title":"Chem. Biol."},{"key":"20_CR25","doi-asserted-by":"crossref","unstructured":"Kalghatgi, S. et al. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in mammalian cells. Sci. Transl. Med. 5 (2013).","DOI":"10.1126\/scitranslmed.3006055"},{"key":"20_CR26","doi-asserted-by":"publisher","first-page":"9625","DOI":"10.1093\/nar\/gky793","volume":"46","author":"A Hangas","year":"2018","unstructured":"Hangas, A. et al. Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of Topoisomerase 2. Nucleic Acids Res. 46, 9625\u20139636 (2018).","journal-title":"Nucleic Acids Res."},{"key":"20_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.tiv.2018.07.012","volume":"52","author":"K Tilmant","year":"2018","unstructured":"Tilmant, K. et al. In vitro screening of cell bioenergetics to assess mitochondrial dysfunction in drug development. Toxicol. Vitr. 52, 374\u2013383 (2018).","journal-title":"Toxicol. Vitr."},{"key":"20_CR28","doi-asserted-by":"publisher","first-page":"101222","DOI":"10.1016\/j.molmet.2021.101222","volume":"51","author":"R Shrestha","year":"2021","unstructured":"Shrestha, R., Johnson, E. & Byrne, F. L. Exploring the therapeutic potential of mitochondrial uncouplers in cancer. Mol. Metab. 51, 101222 (2021).","journal-title":"Mol. Metab."},{"key":"20_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2021.716406","volume":"9","author":"M Herb","year":"2021","unstructured":"Herb, M., Gluschko, A. & Schramm, M. Reactive oxygen species: not omnipresent but important in many locations. Front. Cell Dev. Biol. 9, 1\u201312 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"20_CR30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/03602530600959433","volume":"38","author":"TKH Chang","year":"2006","unstructured":"Chang, T. K. H. & Abbott, F. S. Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab. Rev. 38, 627\u2013639 (2006).","journal-title":"Drug Metab. Rev."},{"key":"20_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep25333","volume":"6","author":"A Maillet","year":"2016","unstructured":"Maillet, A. et al. Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes. Sci. Rep. 6, 1\u201313 (2016).","journal-title":"Sci. Rep."},{"key":"20_CR32","doi-asserted-by":"crossref","unstructured":"Carrasco, R., Castillo, R. L., Gormaz, J. G., Carrillo, M. & Thavendiranathan, P. Role of oxidative stress in the mechanisms of anthracycline-induced cardiotoxicity: effects of preventive strategies. Oxid. Med. Cell. Longev. 2021, 8863789, (2021).","DOI":"10.1155\/2021\/8863789"},{"key":"20_CR33","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/j.bbamem.2013.04.006","volume":"1828","author":"JP Monteiro","year":"2013","unstructured":"Monteiro, J. P. et al. A biophysical approach to menadione membrane interactions: Relevance for menadione-induced mitochondria dysfunction and related deleterious\/therapeutic effects. Biochim. Biophys. Acta\u2014Biomembr. 1828, 1899\u20131908 (2013).","journal-title":"Biochim. Biophys. Acta\u2014Biomembr."},{"key":"20_CR34","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.bbabio.2018.05.019","volume":"1859","author":"S Cadenas","year":"2018","unstructured":"Cadenas, S. Mitochondrial uncoupling, ROS generation and cardioprotection. Biochim. Biophys. Acta\u2014Bioenerg. 1859, 940\u2013950 (2018).","journal-title":"Biochim. Biophys. Acta\u2014Bioenerg."},{"key":"20_CR35","first-page":"3","volume":"44","author":"RZ Zhao","year":"2019","unstructured":"Zhao, R. Z., Jiang, S., Zhang, L. & Yu, Z. Bin. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int. J. Mol. Med. 44, 3\u201315 (2019).","journal-title":"Int. J. Mol. Med."},{"key":"20_CR36","doi-asserted-by":"crossref","unstructured":"Haider, K., Haider, M. R., Neha, K. & Yar, M. S. Free radical scavengers: an overview on heterocyclic advances and medicinal prospects. Eur. J. Med. Chem. 204 (2020).","DOI":"10.1016\/j.ejmech.2020.112607"},{"key":"20_CR37","doi-asserted-by":"crossref","unstructured":"Guengerich, F. P., Liebler, D. C. & Reed, D. L. Enzymatic activation of chemicals to toxic metabolites. Crit. Rev. Toxicol. 14 (1985).","DOI":"10.3109\/10408448509037460"},{"key":"20_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1021\/tx7002273","volume":"21","author":"TA Baillie","year":"2008","unstructured":"Baillie, T. A. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem. Res. Toxicol. 21, 129\u2013137 (2008).","journal-title":"Chem. Res. Toxicol."},{"key":"20_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1021\/ml1000257","volume":"1","author":"L Xu","year":"2010","unstructured":"Xu, L. et al. Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med. Chem. Lett. 1, 209\u2013213 (2010).","journal-title":"ACS Med. Chem. Lett."},{"key":"20_CR40","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/jcph.256","volume":"54","author":"JM Custodio","year":"2014","unstructured":"Custodio, J. M. et al. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin. J. Clin. Pharmacol. 54, 649\u2013656 (2014).","journal-title":"J. Clin. Pharmacol."},{"key":"20_CR41","doi-asserted-by":"crossref","unstructured":"Peng, H. M., Raner, G. M., Vaz, A. D. N. & Coon, M. J. Oxidative cleavage of esters and amides to carbonyl products by cytochrome P450. Arch. Biochem. Biophys. 318, 333\u2013339 (1995).","DOI":"10.1006\/abbi.1995.1237"},{"key":"20_CR42","doi-asserted-by":"crossref","unstructured":"Kohnh\u00e4user, D. et al. Optimization of the central \u03b1-amino acid in cystobactamids to the broad-spectrum, resistance-breaking antibiotic CN-CC-861. J. Med. Chem. 67, 17162\u201317190 (2024).","DOI":"10.1021\/acs.jmedchem.4c00927"},{"key":"20_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/154065802761001293","volume":"1","author":"C Parng","year":"2002","unstructured":"Parng, C., Seng, W. L., Semino, C. & McGrath, P. Zebrafish: a preclinical model for drug screening. Assay Drug Dev. Technol. 1, 41\u201348 (2002).","journal-title":"Assay Drug Dev. Technol."},{"key":"20_CR44","doi-asserted-by":"crossref","unstructured":"Zhu, J. J. et al. Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish. J. Appl. Toxicol. 34, 139\u2013148 (2014).","DOI":"10.1002\/jat.2843"},{"key":"20_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.vascn.2012.10.003","volume":"67","author":"JH He","year":"2013","unstructured":"He, J. H. et al. A zebrafish phenotypic assay for assessing drug-induced hepatotoxicity. J. Pharmacol. Toxicol. Methods 67, 25\u201332 (2013).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"20_CR46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.reprotox.2011.06.121","volume":"33","author":"U Str\u00e4hle","year":"2012","unstructured":"Str\u00e4hle, U. et al. Zebrafish embryos as an alternative to animal experiments\u2014a commentary on the definition of the onset of protected life stages in animal welfare regulations. Reprod. Toxicol. 33, 128\u2013132 (2012).","journal-title":"Reprod. Toxicol."},{"key":"20_CR47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00228-017-2351-y","volume":"74","author":"K Dathe","year":"2018","unstructured":"Dathe, K. & Schaefer, C. Drug safety in pregnancy: the German Embryotox institute. Eur. J. Clin. Pharmacol. 74, 171\u2013179 (2018).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"20_CR48","doi-asserted-by":"crossref","unstructured":"Vargesson, N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res. (Part C) 105, 140\u2013156 (2015).","DOI":"10.1002\/bdrc.21096"},{"key":"20_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0147-6513(91)90017-J","volume":"21","author":"R Nagel","year":"1991","unstructured":"Nagel, R. et al. Effect of 3,4-dichloroaniline on the early life stages of the zebrafish (Brachydanio retio): Results of a comparative laboratory study. Ecotoxicol. Environ. Saf. 21, 157\u2013164 (1991).","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"20_CR50","doi-asserted-by":"crossref","unstructured":"Zakaria, Z. Z. et al. Using Zebrafish for investigating the molecular mechanisms of drug-induced cardiotoxicity. Biomed. Res. Int. 2018 (2018).","DOI":"10.1155\/2018\/1642684"},{"key":"20_CR51","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1365-2125.2004.02194.x","volume":"58","author":"DK Walker","year":"2004","unstructured":"Walker, D. K. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br. J. Clin. Pharmacol. 58, 601\u2013608 (2004).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"20_CR52","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1021\/jacs.7b01072","volume":"139","author":"MH Wright","year":"2017","unstructured":"Wright, M. H., Fetzer, C. & Sieber, S. A. Chemical probes unravel an antimicrobial defense response triggered by binding of the human opioid dynorphin to a bacterial sensor kinase. J. Am. Chem. Soc. 139, 6152\u20136159 (2017).","journal-title":"J. Am. Chem. Soc."},{"key":"20_CR53","doi-asserted-by":"crossref","unstructured":"Perez-Dominguez, F. et al. Role of pirin, an oxidative stress sensor protein, in epithelial carcinogenesis. Biology (Basel) 10, 1\u201313 (2021).","DOI":"10.3390\/biology10020116"},{"key":"20_CR54","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.1002\/chem.202005086","volume":"27","author":"T Seedorf","year":"2021","unstructured":"Seedorf, T., Kirschning, A. & Solga, D. Natural and synthetic oligoarylamides: privileged structures for medical applications. Chem. - A Eur. J. 27, 7321\u20137339 (2021).","journal-title":"Chem. - A Eur. J."},{"key":"20_CR55","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/S0022-2275(20)37413-7","volume":"38","author":"S Xu","year":"1997","unstructured":"Xu, S. et al. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J. Lipid Res. 38, 1289\u20131298 (1997).","journal-title":"J. Lipid Res."},{"key":"20_CR56","first-page":"139","volume":"176","author":"WJ Shen","year":"2018","unstructured":"Shen, W. J., Azhar, S. & Kraemer, F. B. SR-B1: a unique multifunctional receptor for cholesterol influx and efflux. Annu Rev Physiol. 176, 139\u2013148 (2018).","journal-title":"Annu Rev Physiol."},{"key":"20_CR57","doi-asserted-by":"publisher","first-page":"20982","DOI":"10.1074\/jbc.272.34.20982","volume":"272","author":"Y Ji","year":"1997","unstructured":"Ji, Y. et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J. Biol. Chem. 272, 20982\u201320985 (1997).","journal-title":"J. Biol. Chem."},{"key":"20_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2016.00466","volume":"7","author":"LK Mooberry","year":"2016","unstructured":"Mooberry, L. K., Sabnis, N. A., Panchoo, M., Nagarajan, B. & Lacko, A. G. Targeting the SR-B1 receptor as a gateway for cancer therapy and imaging. Front. Pharmacol. 7, 1\u201311 (2016).","journal-title":"Front. Pharmacol."},{"key":"20_CR59","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S1499-3872(13)60099-5","volume":"12","author":"Y Qiu","year":"2013","unstructured":"Qiu, Y. et al. Upregulation of caveolin-1 and SR-B1 in mice with non-alcoholic fatty liver disease. Hepatobiliary Pancreat. Dis. Int. 12, 630\u2013636 (2013).","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"20_CR60","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/ATVBAHA.109.191320","volume":"29","author":"D Masson","year":"2009","unstructured":"Masson, D. et al. Increased HDL cholesterol and ApoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler. Thromb. Vasc. Biol. 29, 2054\u20132060 (2009).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"20_CR61","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/hep.21994","volume":"46","author":"MB Zeisel","year":"2007","unstructured":"Zeisel, M. B. et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46, 1722\u20131731 (2007).","journal-title":"Hepatology"},{"key":"20_CR62","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","volume":"21","author":"E Scarselli","year":"2002","unstructured":"Scarselli, E. et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21, 5017\u20135025 (2002).","journal-title":"EMBO J."},{"key":"20_CR63","unstructured":"WHO. Global HIV Hepatitis and Sexually Transmitted Infections Programmes. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections 2021. (WHO, 2021)."},{"key":"20_CR64","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrmicro3098","volume":"11","author":"BD Lindenbach","year":"2013","unstructured":"Lindenbach, B. D. & Rice, C. M. The ins and outs of hepatitis C virus entry and assembly. Nat. Rev. Microbiol. 11, 688\u2013700 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"20_CR65","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11883-022-01001-1","volume":"24","author":"HR Powers","year":"2022","unstructured":"Powers, H. R. & Sahoo, D. SR-B1\u2019s next top model: structural perspectives on the functions of the HDL receptor. Curr. Atheroscler. Rep. 24, 277\u2013288 (2022).","journal-title":"Curr. Atheroscler. Rep."},{"key":"20_CR66","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1158\/0008-5472.CAN-18-2529","volume":"79","author":"JA Gordon","year":"2019","unstructured":"Gordon, J. A. et al. Upregulation of scavenger receptor B1 is required for steroidogenic and nonsteroidogenic cholesterol metabolism in prostate cancer. Cancer Res. 79, 3320\u20133331 (2019).","journal-title":"Cancer Res."},{"key":"20_CR67","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s42255-020-00324-0","volume":"2","author":"C Wei","year":"2020","unstructured":"Wei, C. et al. HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. Nat. Metab. 2, 1391\u20131400 (2020).","journal-title":"Nat. Metab."},{"key":"20_CR68","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/lt.24349","volume":"22","author":"IA Rowe","year":"2016","unstructured":"Rowe, I. A. et al. Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transplant. 22, 287\u2013297 (2016).","journal-title":"Liver Transplant."},{"key":"20_CR69","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/infdis\/jit503","volume":"209","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski, M. S. et al. Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J. Infect. Dis. 209, 658\u2013667 (2014).","journal-title":"J. Infect. Dis."},{"key":"20_CR70","doi-asserted-by":"crossref","unstructured":"MacLeod, A. K. et al. Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism.Proc. Natl. Acad. Sci. 121, e2315069121 (2024).","DOI":"10.1073\/pnas.2315069121"},{"key":"20_CR71","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1128\/JVI.03074-15","volume":"90","author":"S Haid","year":"2016","unstructured":"Haid, S., Grethe, C., Bankwitz, D., Grunwald, T. & Pietschmann, T. Identification of a human respiratory syncytial virus cell entry inhibitor by using a novel lentiviral pseudotype system. J. Virol. 90, 3065\u20133073 (2016).","journal-title":"J. Virol."},{"key":"20_CR72","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","volume":"72","author":"T Dull","year":"1998","unstructured":"Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463\u20138471 (1998).","journal-title":"J. Virol."},{"key":"20_CR73","doi-asserted-by":"crossref","unstructured":"Vieyres, G. et al. ABHD5\/CGI-58, the chanarin-dorfman syndrome protein, mobilises lipid stores for hepatitis C virus production. PLoS Pathog. 12, e1005568 (2016).","DOI":"10.1371\/journal.ppat.1005568"},{"key":"20_CR74","doi-asserted-by":"publisher","first-page":"13072","DOI":"10.1128\/JVI.78.23.13072-13081.2004","volume":"78","author":"HM Pham","year":"2004","unstructured":"Pham, H. M., Arga\u00f1araz, E. R., Groschel, B., Trono, D. & Lama, J. Lentiviral vectors interfering with virus-induced CD4 down-modulation potently block human immunodeficiency virus type 1 replication in primary lymphocytes. J. Virol. 78, 13072\u201313081 (2004).","journal-title":"J. Virol."},{"key":"20_CR75","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/hep.26567","volume":"59","author":"S Haid","year":"2014","unstructured":"Haid, S. et al. Isolate-dependent use of claudins for cell entry by hepatitis C virus. Hepatology 59, 24\u201334 (2014).","journal-title":"Hepatology"},{"key":"20_CR76","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1006\/viro.2001.0903","volume":"284","author":"I Kalajzic","year":"2001","unstructured":"Kalajzic, I. et al. Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor cells. Virology 284, 37\u201345 (2001).","journal-title":"Virology"}],"container-title":["npj Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00020-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:10:47Z","timestamp":1757344247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00020-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20"],"URL":"https:\/\/doi.org\/10.1038\/s44386-025-00020-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.10.617689","asserted-by":"object"}]},"ISSN":["3005-1452"],"issn-type":[{"value":"3005-1452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}